Vaidya Sane Ayurved FY26 Net Profit Rises 25.7% to ₹8.99 Cr
Vaidya Sane Ayurved Laboratories Limited reported a 25.7% increase in consolidated net profit to ₹8.99 crore for FY26, while revenue from operations rose 18.9% to ₹106.91 crore. The company approved the acquisition of Parasnath Healthcare for ₹6 crore to strengthen its franchisee clinic operations. Looking ahead, management targets revenue of ₹170 crore to ₹180 crore for FY27 and aims to scale towards ₹250 crore to ₹300 crore by FY28 with EBITDA margins above 20%.
*this image is generated using AI for illustrative purposes only.
Vaidya Sane Ayurved Laboratories Limited reported its audited standalone and consolidated financial results for the year ended March 31, 2026. The company achieved a consolidated net profit of ₹8.99 crore, a 25.7% increase from ₹7.15 crore in the previous year. Revenue from operations rose by 18.9% to ₹106.91 crore, driven by sustained patient additions and the strengthening of its clinical network.
Consolidated Financial Performance
On a consolidated basis, the company reported an EBITDA of ₹15.42 crore for FY26, compared to ₹14.32 crore in FY25. Profit before tax stood at ₹10.81 crore against ₹9.90 crore in the prior year. The board approved the results at a meeting held on May 15, 2026.
| Metric (₹ Crore) | FY26 | FY25 | YoY Change |
|---|---|---|---|
| Income from Operations | 106.91 | 89.92 | 18.89% |
| Total Income | 106.91 | 89.92 | 18.89% |
| Total Expenditure | 91.49 | 75.60 | 21.02% |
| EBITDA (Excl. Other Income) | 15.42 | 14.32 | 7.63% |
| Profit Before Tax | 10.81 | 9.90 | 9.16% |
| Profit After Tax | 8.99 | 7.15 | 25.66% |
| Basic EPS (₹) | 8.51 | 6.78 | 25.52% |
Operational Highlights
For the half year ended March 31, 2026 (H2 FY26), revenue from operations grew 18.4% year-on-year to ₹56.96 crore from ₹48.12 crore in H2 FY25. Net profit for the half year was ₹4.15 crore. The company noted that while profitability was impacted by higher investments in expansion and technology, gross margins remained robust at over 82%.
Strategic Acquisition
The Board approved the acquisition of 100% shares of Parasnath Healthcare (OPC) Private Limited for a cash consideration of ₹6 crore. The target entity, focused on speciality healthcare services for knee pain and clinic operations, reported a turnover of ₹14.02 crore for FY25-26. The acquisition aims to consolidate franchisee clinic operations and strengthen the company's presence in the healthcare segment.
Outlook
Management stated that the demand for preventive and chronic care management through Ayurveda remains encouraging. By 2030, the company aims to establish 1,000 clinics, 10 hospitals, and 5,000 outpatient departments, with a focus on expanding its presence in rural India. For FY27, the company targets revenue of approximately ₹170 crore to ₹180 crore, with medium-term goals to scale revenues towards ₹250 crore to ₹300 crore by FY28 while aiming for EBITDA margins above 20%.
Historical Stock Returns for Vaidya Sane Ayurved Laboratories
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +8.04% | -4.36% | -28.91% | -35.04% | +15.18% | +69.50% |
How does Vaidya Sane Ayurved Laboratories plan to fund the aggressive expansion to 1,000 clinics and 10 hospitals by 2030 without significantly diluting margins or equity?
Will the acquisition of Parasnath Healthcare create a replicable template for consolidating other franchisee clinic operations, and how many similar acquisitions could be in the pipeline?
Given that total expenditure grew faster (21%) than revenue (18.9%), what specific cost optimization measures will management implement to achieve EBITDA margins above 20% by FY28?
20
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
